Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study

Abdulla Watad, Yoav Elizur, Or Hen, Paula David, Yonatan Shneor Patt, Omer Gendelman, Amit Nachman, Alen Zabotti, Merav Lidar, Dennis McGonagle, Howard Amital · 2026

Read Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study by Abdulla Watad, Yoav Elizur, Or Hen, Paula David, Yonatan Shneor Patt, Omer Gendelman, Amit Nachman, Alen Zabotti, Merav Lidar, Dennis McGonagle, Howard Amital (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13157781.txt.

Description

Abdulla Watad and colleagues report a 2026 cohort study on skin and joint disease. People with psoriasis, a long-term skin condition, face a higher risk of later developing arthritis in their joints. Modern biologic drugs can calm the skin disease, but it was not clear whether the class of drug, or the order in which drugs are tried, changes that joint risk.

The team followed 2,819 patients who started biologic treatment between 2002 and 2022. About fourteen percent went on to develop joint disease. One drug class used first was linked with a much lower risk than the older standard drugs. Among patients who moved to a second drug, a different class showed the clearest drop in risk. The results may help doctors pick a first and second drug with joint protection in mind.

Catalog record

CREATORAbdulla Watad, Yoav Elizur, Or Hen, Paula David, Yonatan Shneor Patt, Omer Gendelman, Amit Nachman, Alen Zabotti, Merav Lidar, Dennis McGonagle, Howard Amital
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13157781

Browse the full library · About the Tower of Babel